米非司酮联合甲基睾丸素治疗子宫肌瘤的临床观察

目的探讨米非司酮联合甲基睾丸素在治疗子宫肌瘤方面的临床效果。方法将米非司酮联合甲基睾丸素治疗的198例子宫肌瘤患者作为研究对象,分析并随访患者治疗前后的相关生命体征。结果患者的促卵泡生成激素(FSH)、黄体生成素(LH)、雌激素(E2)、孕酮(P)F等数据明显降低,差异有统计学意义(P<0.05);雄激素(T)的改变情况不明显,差异无统计学意义;治疗前后子宫体及瘤体大小的变化比较,两者治疗后均明显缩小,差异具有统计学意义(P<0.05);治疗后血红蛋白明显高于治疗前,差异具有统计学意义(P<0.05)。有2例复发。结论米非司酮联合甲基睾丸素治疗子宫肌瘤疗效显著,具有较高的安全度,并可纠正患者贫血症状,值得推广采用。

Objective To study the clinical effect of mifepristone combined with methyl testosterone treating hysteromyoma. Method 198 patients with hysteromyoma treated by mifepristone combined with methyl testosterone were selected as the research objects. Related vital signs of patients before and after treatment were analyzed and followed up. Results FSH, LH, E 2, P levels in patients were significantly decreased, and the difference was statistically significant （P〈0.05）;Testosterone （T） change was not obvious, and there was no statistically significant difference;Changes before and after treatment of uterine body and the size of the tumors compared with after treatment were significantly reduced, with statistically significant difference （P〈0.05）;Hemoglobin after treatment were significantly higher than those before treatment, and the difference was statistically significant （P〈0.05）. There were 2 cases of recurrence. Conclusion The curative effect of mifepristone in combination with methyl testosterone treating hysteromyoma is distinct, has a high degree of safety, and may correct anemia symptoms in patients, and it is worth being promoted.